The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Adynxx sales in the US from 2017 to 2023, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Smarter leaders trust GlobalData
Adynxx Inc (Adynxx), formerly Alliqua BioMedical, Inc, is a clinical-stage biopharmaceutical company. It utilizes AYX transcription factor decoys to create therapies with disease-changing properties. The company carries out the development of transcription factor decoy technology and markets novel, disease-modifying products to provide unmet needs in the treatment of pain and inflammation. Adynxx’s AYX platform finds applications across multiple diseases to create non-opioid therapeutics for the treatment of pain. The company collaborates with artificial intelligence-driven drug discovery partners and evaluates licensing opportunities to expand its pipeline and leverage its business development, clinical development and regulatory expertise. Adynxx is headquartered in San Francisco, California, the US. Key subsidiaries of Adynxx include AquaMed Technologies.
The key metrics of Adynxx related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2023 are shown below:
As Adynxx is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Adynxx.
For a detailed understanding of the performance of Adynxx, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s revenue report leverages GlobalData’s SKU tracker, which contains real-world, purchasing data from the US healthcare institutions.
